ArticleClinical, cosmetic and investigational dermatology2026
ALK-Negative Systemic Anaplastic Large Cell Lymphoma with Cutaneous Involvement Initially Mimicking Primary Cutaneous Disease: A Case Report.
Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anaplastic large cell lymphoma (ALCL), a subgroup of T-cell non-Hodgkin's lymphoma, is a relatively uncommon malignancy with a highly variable prognosis. Systemic ALK-negative status and high Ki-67 expression are generally associated with poor outcomes in ALCL patients. Systemic ALK-negative ALCL presenting initially with cutaneous involvement is rare, with only a few cases reported in the literature. The aggressive clinical course of systemic ALK-negative ALCL with cutaneous lesions contrasts sharply with the indolent behavior of primary cutaneous ALCL (C-ALCL). Accurate distinction requires integration of histopathological and immunophenotypic findings. In particular, negativity for cutaneous lymphocyte antigen (CLA) is a useful discriminator, as primary C-ALCL typically expresses CLA while systemic cases often do not. Accumulating more clinical data is essential to better characterize this entity and guide therapeutic decisions. Here, we report a case of aggressive ALK-negative systemic ALCL that presented with cutaneous nodules as the initial manifestation, clinically mimicking primary C-ALCL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.